Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
SparingVision logo — Genomic Medicines For Ocular Diseases

SparingVision

Genomic Medicines For Ocular Diseases

Founded 2016 France France 49 employees Series B Total: $119.50M Biotechnology, Health Care +1

General Information

Company Name SparingVision
Founded Year 2016
Location France France
Founders / Decision Makers
Team member
Employees 49
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with SparingVision. To contact SparingVision, visit sparingvision.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SparingVision compare?

A PDF of SparingVision and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SparingVision soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SparingVision

SparingVision is a biotechnology startup dedicated to developing genomic medicines for ocular diseases. Founded in 2016, the company aims to revolutionize the treatment of ocular diseases by translating over 20 years of world-leading ophthalmic research into vision-saving therapies. The core focus of SparingVision's work is on addressing rod-cone dystrophies, specifically targeting retinitis pigmentosa (RP), the most common inherited retinal disease globally, affecting two million people. The company's lead products, SPVN06 and SPVN20, are designed to address mid and late stages of RP, offering potential applications for various retinal diseases, irrespective of genetic cause. Notably, SparingVision has attracted significant investments amounting to a total of €60 million from a strong syndicate of backers including 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital, and Ysios Capital. Most recently, the company secured a €75.00M Series B investment on 14 September 2022 with participation from 4BIO Capital, Bpifrance, Jeito Capital, Ysios Capital, Retinal Degeneration Fund, and UPMC Enterprises. Based in France, SparingVision is supported by a strong, internationally renowned team committed to leveraging the potential of genomic medicine to rapidly deliver new treatments to ocular disease patients. With a focus on gene independent treatments, SparingVision is poised to bring about a paradigm shift in ocular disease therapeutics. For more information, visit www.sparingvision.com.

Business keywords: Genomic Medicines, Ocular Diseases, Inherited Retinal Diseases, Gene-independent Treatments, Research and Development, Retinitis Pigmentosa, Vision-Saving Treatments, Investment, Therapeutic Innovation, Pipeline Development, Rare Disease Treatment, International Collaboration, Sight-saving Treatments, Venture Capital

Services & Products

Development and delivery of innovative genomic medicines for ocular diseases

Target Customers

Patients affected by inherited retinal diseases and ocular disorders

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €75.00M 6
4BIO Capital Bpifrance Jeito Capital
4BIO Capital, Bpifrance +4
14 Sep 2022
Corporate Round Undisclosed 1
Intellia Therapeutics
Intellia Therapeutics
13 Oct 2021
Series A €44.50M 3
4BIO Capital Foundation Fighting Blindness Jeito Capital
4BIO Capital, Foundation Fighting Blindness +1
21 Oct 2020

SparingVision Alternatives & Competitors

View All Alternatives
SparingVision vs
GenSight Biologics
GenSight Biologics France

Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerati...

Post-IPO Equity
34 employees
Biotechnology, Health Care
Compare SparingVision vs GenSight Biologics
SparingVision vs
AAVantgarde
AAVantgarde

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care
Compare SparingVision vs AAVantgarde
SparingVision vs
RetroSense Therapeutics
RetroSense Therapeutics

Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel g...

Series B
1 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About SparingVision

Genomic Medicines For Ocular Diseases
SparingVision was founded in 2016.
SparingVision is headquartered in France.
SparingVision operates in Biotechnology, Health Care and Life Sciences. Its work centres on Genomic Medicines, Ocular Diseases, Inherited Retinal Diseases and Gene-independent Treatments. Its customers include Patients affected by inherited retinal diseases and ocular disorders.
SparingVision has approximately 49 employees.
SparingVision has completed 3 funding rounds, raising a total of $119.50M. The latest funding stage is Series B.
SparingVision offers: Development and delivery of innovative genomic medicines for ocular diseases.
Top alternatives and competitors to SparingVision include GenSight Biologics, AAVantgarde, RetroSense Therapeutics, Homology Medicines, Reborna Biosciences, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SparingVision and GenSight Biologics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SparingVision, https://bouncewatch.com/company/sparingvision, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout